Local generic drug giant Mylan saw first-quarter profits surge on higher revenue that was boosted by acquisitions but hurt by lower EpiPen sales.

Net income quadrupled to $66.4 million, or 12 cents per share, up from $13.9 million, or 3 cents, in the same quarter last year.

Excluding special items, adjusted earnings rose 22 percent to 93 cents per share from 76 cents, in line with Wall Street estimates.

Revenue rose 24 percent to $2.72 billion from $2.19 billion a year ago, missing the average estimate of $2.84 billion. Revenue was aided by the acquisition of Meda AB and dermatological products from Renaissance Acquisition Holdings.

Advertise with us

The revenue gains were offset by lower sales of the EpiPen allergy shot, which has drawn outrage among patients and lawmakers because of a 500 percent price increase in recent years.

In a conference call with analysts Wednesday, the company said EpiPen sales fell an undisclosed amount during the quarter because of increased competition and Mylan’s launch of a half-price generic EpiPen in December. Mylan started selling the identical generic version in response to the outcry over the price of the brand name product.

Sales in the company’s North America segment rose 5 percent, but would have been up 20 percent excluding EpiPen results, Mylan said.

Mylan shares lost 79 cents, or 2 percent, in early trading, to $37.22.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.